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Research Paper

A genome-wide association study of cocaine use
disorder accounting for phenotypic heterogeneity
and gene–environment interaction
Jiangwen Sun, PhD, BM; Henry R. Kranzler, MD; Joel Gelernter, MD; Jinbo Bi, PhD

Background: Phenotypic heterogeneity and complicated gene–environment interplay in etiology are among the primary factors that
hinder the identification of genetic variants associated with cocaine use disorder. Methods: To detect novel genetic variants associated with cocaine use disorder, we derived disease traits with reduced phenotypic heterogeneity using cluster analysis of a study sample (n = 9965). We then used these traits in genome-wide association tests, performed separately for 2070 African Americans and
1570 European Americans, using a new mixed model that accounted for the moderating effects of 5 childhood environmental factors.
We used an independent sample (918 African Americans, 1382 European Americans) for replication. Results: The cluster analysis
yielded 5 cocaine use disorder subtypes, of which subtypes 4 (n = 3258) and 5 (n = 1916) comprised heavy cocaine users, had high
heritability estimates (h2 = 0.66 and 0.64, respectively) and were used in association tests. Seven of the 13 identified genetic loci in the
discovery phase were available in the replication sample. In African Americans, rs114492924 (discovery p = 1.23 × E−8), a single nucleotide polymorphism in LINC01411, was replicated in the replication sample (p = 3.63 × E−3). In a meta-analysis that combined the
discovery and replication results, 3 loci in African Americans were significant genome-wide: rs10188036 in TRAK2 (p = 2.95 × E−8),
del-1:15511771 in TMEM51 (p = 9.11 × E−10) and rs149843442 near LPHN2 (p = 3.50 × E−8). Limitations: Lack of data prevented us
from replicating 6 of the 13 identified loci. Conclusion: Our results demonstrate the importance of considering phenotypic heterogeneity and gene–environment interplay in detecting genetic variations that contribute to cocaine use disorder, because new genetic
loci have been identified using our novel analytic method.

Introduction
Cocaine is among the most widely abused illicit drugs in the
United States. 1 The National Survey on Drug Use and
Health2 showed that in 2015, 0.7% of people aged 12 or older
were cocaine users, an increase from 0.6% in 2014. Cocaine
use is associated with serious health and social problems and
is very costly to society, reflected in the fact that it is the illicit
drug associated with the highest number of emergency department visits.3
Susceptibility to cocaine use disorder (CUD) includes a genetic
component. Heritability of the 3 CUD-related traits — cocaine
use, abuse and dependence — was estimated to be 0.39, 0.79
and 0.65, respectively, in female twins.4 Similar estimates in
male twins were 0.61, 0.32 and 0.79, respectively.5 However,
despite evidence of the heritability of CUD, there have been
few efforts to identify specific genetic risk factors for the disorder.6 Several data sets with CUD traits have been used for
genome-wide genotyping.7–9 To date, a single nucleotide poly-

morphism (SNP), rs2629540 mapping to FAM53B, has been associated genome-wide with CUD,9 an association for which
consistent results in an animal model were later obtained.10
More than 10 biological processes, with more than 100 genes
involved, may play roles in the etiopathology of substance
use disorders.11 Variation in any of these genes — and indeed
in other genes with an unrecognized relationship to these
traits — could contribute to the development of a substance
use disorder. Substance use disorders are heterogeneous and
phenotypically and genetically complex, hindering the identification of specific genetic risk factors. In addition, multiple
studies have shown that the genetic risk for developing a
substance use disorder can be moderated by environmental
factors such as stressful life events, neighbourhood stability,
religiosity and peer drug use.12–18 Thus, the statistical power
of genome-wide association studies (GWAS) to identify the
genetic variation contributing to the risk of substance use disorders is limited by the extent to which environmental effects
and phenotypic heterogeneity are unaccounted for.
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In this study, we sought to identify genetic variants associated with CUD by conducting a GWAS using comparatively
homogeneous subtypes and considering gene–environment
interactions. We first performed multivariate cluster analysis
using a discovery sample of 9965 participants for which we
had a comprehensive clinical assessment. The analysis
grouped cocaine users into homogeneous subgroups (i.e.,
subtypes) based on their clinical manifestations. We used
the likelihood of membership in 2 highly heritable subtypes
of CUD as traits in a subsequent GWAS and compared
them with an ordinal trait derived by counting how many
of the 11 diagnostic criteria for CUD in the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
were present.19 We used a similar method to reduce phenotypic heterogeneity in a previous linkage study of cocaine
dependence.20
Most of the participants were genotyped with genomewide markers. We performed separate GWASs in 2070 African Americans (AAs) and 1570 European Americans (EAs) to
identify SNPs associated with CUD. In the analyses, we also
considered 5 childhood environmental factors, including
nontraditional parental care, change in residence, traumatic
experience, the presence of household drinking and illicit
drug use, and the presence of household tobacco use. We
used an independent sample of 918 AAs and 1382 EAs to
replicate our findings, followed by a meta-analysis that combined the discovery and replication results.
All of our notable findings were observed in the AA population only. We identified more associations using the clusteranalysis-derived CUD traits than using the DSM-5 diagnostic
criterion count. For all but 1 genetic locus, the genome-wide
significant (GWS) findings were moderated by 1 of the 5 environmental factors and could not be detected with main
effect association tests.

Methods
Participants and diagnostic procedures
A total of 11 000 participants were recruited for family-based
(n = 2468 from 1047 small nuclear families) and case–control
(n = 8532) genetic studies of opioid, cocaine or alcohol
dependence. Participants were recruited at 5 sites in the eastern United States: Yale University School of Medicine (n =
5067), the University of Connecticut Health Center (n = 3765),
the University of Pennsylvania School of Medicine (n = 1306),
the Medical University of South Carolina (n = 607) and
McLean Hospital (n = 255).
The institutional review board at each site approved all
procedures; certificates of confidentiality were obtained from
the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, and all participants
gave written informed consent to participate. Interviews
were conducted using the Semi-Structured Assessment for
Drug Dependence and Alcoholism (SSADDA), 21,22 a
computer-assisted interview that yields lifetime diagnoses for
cocaine dependence and other major psychiatric traits using
DSM-IV criteria.23 The reliability of the cocaine dependence

diagnosis was excellent, with test–retest reliability of κ = 0.92
and inter-rater reliability of κ = 0.83.21
The reliability of the individual cocaine dependence cri
teria ranged from κ = 0.47 to 0.60.22 The SSADDA also covers criteria for cocaine abuse, 3 of which are included in the
DSM-5 diagnosis of CUD. These 3 criteria, together with
craving and the 7 DSM-IV criteria, were used to develop an
ordinal DSM-5 CUD diagnostic trait.19 Moreover, a variety of
other clinical features associated with cocaine use are queried
in the SSADDA. The variables used in the subtyping (i.e.,
cluster analysis) procedure combined these clinical features.
Finally, we included early childhood data in the analysis,
obtained using the SSADDA environmental history section.

CUD subtypes
We used clinical data for 9965 participants (of the 11 000 total)
— consisting of 2379 participants from 1099 small nuclear
families and 7586 unrelated individuals — in the multivariate
cluster analysis to develop CUD subtypes. We derived subtypes using 25 questions from the SSADDA cocaine section,
which yielded 160 variables covering the following areas: (1)
age of onset, frequency and intensity of cocaine use; (2) route
of cocaine administration; (3) occurrence of psychosocial and
medical consequences of cocaine use; (4) attempts to quit cocaine use; and (5) cocaine treatment history. We used 68 key
variables from the 25 survey questions to generate clusters
(see Bi and colleagues24 for a full description of the features
used in the subtyping procedure). We used demographic and
other substance use and psychiatric variables and disorders
obtained from the SSADDA interview, together with herit
ability estimates, to characterize and evaluate the concurrent
validity of the resultant clusters.
Differentiating the subtypes was a 2-phase process. Each
phase comprised 3 consecutive steps: data reduction, cluster
analysis and heritability estimation. We retained clusters from
phase 1 with no cocaine-related features or a high heritability
estimate (> 0.6) and merged the remaining clusters for use in
the second phase. The second phase included only cocaine
users as a means of refining the clusters. During each phase,
we used multiple correspondence analysis (MCA)25,26 to reduce the large number of variables. We retained the top MCA
dimensions that cumulatively explained 60% of the variance in
each phase, leaving the top 25 MCA components in phase 1
and the top 41 in phase 2. We then used cluster analysis to
group similar participants based on the retained dimensions.
We first obtained 100 relatively small clusters using the Kmedoids clustering method.27,28 These acted as intermediate
clusters, to which we applied the agglomerative hierarchical
clustering method,29,30 merging them into 5 clusters using
Wald’s aggregation criterion and the Euclidean distance to
compute the similarities between each pairs of intermediate
clusters for merging. We determined the final number of clusters by manually inspecting the clinical characteristics of the
resultant clusters at the different levels (from the 6-cluster level
to 3-cluster level) of the clustering dendrogram. We constructed a probabilistic classifier using logistic regression and
the 68 variables from the cluster analysis to separate
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 articipants in each cluster from those in other clusters. The
p
classification probability provided an estimated likelihood of
subtype membership for each participant, a continuous outcome variable of 0 to 1 that reflected the membership likelihood in each subtype. This likelihood measure reflects the
phenotypic heterogeneity among the individuals in a cluster
and those outside the cluster, providing a quantitative trait related to CUD rather than a qualitative trait. We estimated
narrow-sense heritability for this quantitative trait for each
subtype (cluster) using the “polygenic” function in the software package Sequential Oligogenic Linkage Analysis Routine
(SOLAR)30 and the pedigrees of the sample participants.
We performed GWAS using the 2 most severe and highly
heritable subtypes to maximize the likelihood of finding
genetic associations. For participants in the GWAS or the replication analysis who were not included in the cluster analysis,
we used the constructed classifier to calculate the trait value
(i.e., the likelihood of the participants’ membership in a subtype based on the clinical variables).

Environmental measures
There are 33 questions in the SSADDA environment section
that cover information on 11 major childhood environmental
factors (e.g., change in residence, experience of violence, experience of sexual abuse, household drinking and illicit drug
use). For the majority of the environmental factors, less than
23% of individuals in both the GWAS and replication samples were exposed (i.e., had a positive response). Because the
small sample size yielded limited power to detect an effect,
we limited the analysis to the 4 environmental factors for
which the number of exposed participants exceeded 55% in
both samples. There were also 3 important SSADDA
environmental variables. Although they were endorsed by a
very limited number of genotyped participants, we created a
composite factor consisting of these 3 variables to increase
the power to detect genetic association.
We derived a binary variable for each environmental factor.
We evaluated “nontraditional parental care” based on the
question, “Who was the main person taking care of you when
you were growing up (before age 18)?” and considered the
variable positive when the answer was anything other than
“both mother and father.” These other responses included
“mother or father plus step-parent,” “mother,” “father,”
“grandmother,” “older brother or sister,” “other relative,”
“foster parent” and “adoptive parent.” Nontraditional parental care defined here is closely related to parental separation,
which has been linked to an increased likelihood of substance
abuse or dependence, including illicit drug abuse.31,32
We evaluated “Change in residence” based on the question, “How many times did you move by age 13?” and considered the variable negative when the answer was “none.”
Frequent residence change increases the chance of social disruption and exposure to diverse social norms and neighbourhoods. Social norms have been shown to have a predictive
association with substance use.33,34 Neighbourhood instability
has long been linked to drug use and dealing, as well as individual delinquency.35–37

36

We created a composite factor — “traumatic experience” —
based on responses to 3 SSADDA questions: “Did you ever
witness or experience a violent crime, like a shooting or a
rape, by age 13?,” “By the time you were age 13, were you
ever sexually abused?,” and “By the time you were age 13,
were you ever beaten by an adult so badly that you needed
medical care or had marks on your body that lasted for more
than 30 days?” We considered this composite factor to be
positive if the response to any of the 3 questions was yes.
Childhood experiences of violent crime and sexual and physical abuse have been linked to an increased risk in adults of
using substances, including cocaine.38,39
We evaluated “household drinking and illicit drug use”
based on the question, “Were you ever aware of adults in your
household drinking enough to get drunk, or using drugs or alcohol, by the time you were 13?” and considered the variable
positive when the answer was yes. There is substantial evidence showing that a family history of drinking or illicit drug
use predicts similar behaviours in offspring or siblings.40,41
Finally, we evaluated “household tobacco use” based on
the question, “Were any members of your household regular
cigarette smokers by the time you were 13?” and considered
the variable positive when the answer was yes. Although a
family history of smoking has not been directly linked to the
use of cocaine in offspring, it does have a predictive effect on
cannabis use in offspring.35,42

Genotyping and quality control
The sample used in the GWAS discovery phase was selected
from among 5540 participants following quality control,9,43,44
and included 3640 individuals (2070 AAs; 1570 EAs) who had
been exposed to cocaine and for whom we had data on the
environmental variables. The replication sample included
2300 individuals with cocaine exposure (918 AAs, 1382 EAs)
who were a subset of a larger sample that was genotyped using
an exome microarray (n = 3675, following quality control).
The GWAS data were obtained using the Illumina
HumanOmni1-Quad v1.0 microarray, which contains 988 306
autosomal SNPs, at the Center for Inherited Disease Research
and the Yale Center for Genome Analysis. Genotypes were
called using GenomeStudio software v2011.1 and genotyping
module v1.8.4 (Illumina). Individuals in the exome microarray
were genotyped with the Infinium CoreExome-24 Kit (Illumina), and genotypes were called using GenCall software
(Illumina). After a series of quality-control steps, the data set
included 5540 individuals and 889 659 SNPs with GWAS data,
and 3625 individuals and 261 746 SNPs with exome microarray
data for imputation. Imputation was performed with
I MPUTE2 45 using the 1000 Genomes reference panel
(www.1000genomes.org/; released March 2012).46 For both
discovery and replication samples, a total of 47 104 916 variants
were imputed. We limited the association analysis to imputed
variants with an imputation quality (INFO) score of r2 > 0.8.
To verify and correct any misclassification of self-reported
race, we compared the GWAS (and exome microarray) data
from all participants with genotypes from the HapMap 3 reference populations CEU, YRI and CHB. We conducted principal
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components analysis in the discovery and replication samples
separately. To choose variants for the principal components
analysis for each sample set, we first filtered out variants with
a minor allele frequency less than 3% and INFO score r2 < 0.99.
Then we identified SNPs that were common in our data sets
and in the HapMap panel. Finally, we pruned SNPs in close
linkage disequilibrium (i.e., r2 < 0.80%). This left 265 043 SNPs
in the GWAS data set and 53 450 SNPs in the exome micro
array data set for the principal components analysis. In both
data sets, the first principal component distinguished AAs and
EAs, aligning well with self-reported race, with few mismatching cases (Appendix 1, Figures S1 and S2, available at jpn.
ca/180098-a1). We used the K-means clustering method in the
first principal component dimension to partition the samples
in both data sets into AAs and EAs (Appendix 1, Table S1). All
subsequent association analyses were conducted separately by
population group, with the first 3 principal components used
to correct for residual population stratification.
We estimated the genetic relationship among participants
separately for the discovery and replication samples using
the linkage-disequilibrium adjusted kinships software,47
which takes into account linkage disequilibrium among the
genetic variants. For both sample sets, only variants with a minor allele frequency of 3% or greater and INFO score r2 ≥ 0.99
were used in the genetic relationship estimation. There were
3 104 531 and 604 884 such variants in the GWAS and exome
microarray data sets, respectively.

Statistical analysis
Traditionally, to identify gene–environment interaction, the
following multiple regression model is used:
yi = β0 + β1ei + β2gi + β3ei × gi
where i indicates the ith participant in the data; ei and gi represent the environmental factor value and genotype of interest of the ith participant, respectively; ei × gi is the interaction
of the 2; and the βs are the model parameters.48 This model
can also consider covariate effects and model residual, which
we omitted to simplify the subsequent notations. An estimated value of β3 that differs significantly from zero indicates
that e and g have an interactive effect on y. Our goal was to
test whether g had an influence on y when a moderating
effect of e was taken into account. Therefore, we excluded the
g term and adopted the following model:
yi = β0 + β1ei + β2ei × gi (1)
In our data, all environmental factors were binary (i.e., ei
took a value of 1 or 0). Plugging 0 and 1 into model 1 to
replace ei, we had:
yi |(ei = 0) = β0
yi |(ei = 1) = (β0 + β1) + β2gi
So, a significant nonzero β2 would indicate that g had an
effect on y in the presence of e.

In our analyses, we accounted for both fixed effects from
several covariates (e.g., age and sex) and a random effect
from genetic relationship among individuals using a mixed
model adapted from model 1 as follows:
yi = β0 + β1ei + β2ei × gi + αci + zi + εi (2)
where ci was the vector of values that the ith participant
had for the covariates of interest; α was the vector that contained model coefficients of these covariates; zi represented
the random genetic effect; and εi was the model residual. To
answer the question of whether the genetic association identified with model 2 was due only to the effect of the variant
itself (i.e., with no effect of the environmental variable), we
tested variants that reached GWS status (p < 5 × 10−8) in the
discovery phase using the following mixed model:
yi = β0 + β1 gi + αci + zi + εi (3)
This model essentially tested the main effect of g without
considering a moderating effect of any environmental factors.
Comparing the test results from these 2 models indicated
whether the genetic association was due to the variant alone
or the gene × environment effect.
In addition to the 3 principal components, age and sex
were included as covariates in all analyses. The genetic relationship values between each pair of participants form a
matrix. We included this genetic relationship matrix in the
analyses as the variance component corresponding to the
term zi in models 2 and 3 to account for the genetic relationship random effect. All association tests were performed
using Gemma software,49 which allowed use of the genetic
relationship matrix in the association models. We performed
meta-analysis to combine association results from the discovery and replication phases using METAL.50
We tested 3 quantitative CUD-related traits in our study:
the DSM-5 diagnostic criterion count and the membership
likelihood scores for subtypes 4 and 5. All participants in the
sample were phenotyped for these 3 traits, including those
who met no or very few diagnostic criteria and would be
considered to be healthy controls according to a diagnostic
standard such as the DSM-IV. In contrast, only participants
who were ever exposed to cocaine and passed quality control
(see Genotyping and quality control, above) were included in
the association analysis.

Results
Table 1 provides sample sizes by site and population group;
the numbers in parentheses indicate the number of participants in the subtyping analysis. Sample characteristics are included in Table 2 (additional information about the sample
has been published previously24).
We identified 5 subtypes through cluster analysis, 4 of
which included cocaine users. The most highly heritable,
heavy-cocaine-use clusters were subtypes 4 and 5: narrowsense heritability (h2) was 0.66 and 0.64, respectively; and
98.4% and 99.5% of participants met DSM-IV cocaine
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29 (26)

0
26 (26)

1333 (1264)
1737 (1697)

355 (349)
0

237 (223)
333 (321)

18 (18)
31

814
Total

189
748

4736

Penn

4415

0
4 (4)
6 (6)
16 (15)
17 (16)
21
118
McLean Hospital

114

12 (12)

2 (2)
46 (41)

614 (588)
680 (665)

34 (28)
18 (18)

121 (114)
113 (111)

14 (14)
16

466

324
MUSC

256

1589
UConn

1643

AA

15 (12)
643 (605)

EA
AA

662 (649)
82 (76)

EA
AA

171 (162)
280

Other

Yale

EA
AA

1957

Recruiting site

2213

Unrelateds
SNFs

GWAS sample*

Subtyping
sample

Table 1: Sample size by phase, site and population group
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AA = African American; EA = European American; GWAS = genome-wide association study; MUSC = Medical University of South Carolina; Penn = University of Pennsylvania; SNF = small nuclear family; UConn = University of
Connecticut.
*Numbers in parentheses indicate the number of participants used in the subtyping analysis. Note that due to overlap between the subtyping sample set and the set used in the GWAS study, numbers in each row do not
necessary correspond to the total columns on the right.

11 000

1306
423

5306
5188

863
296 (67)

1349 (741)
879 (600)

215 (112)
0

33 (24)

607

3765

255
116
120
0
0
0

263

1830
1666

331
4 (4)

216 (208)
184 (176)

4 (4)
0

18 (17)

Total
EA

2674
2208

AA
EA

833 (462)
476 (308)

AA
EA

15 (7)

Total
Unrelateds
SNFs

Replication sample*

5067
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 ependence diagnostic criteria, respectively (Appendix 1, Table S2). Subtype 4
d
was the largest cocaine use subgroup (n = 3258), characterized by a low rate of
intravenous cocaine injection (lowest among the 4 cocaine use subtypes, Appendix 1, Table S3). Subtype 5 (n = 1916) included participants who used cocaine
most heavily, were most likely to use it intravenously and had the most adverse
effects from their cocaine use (e.g., 74.0% of participants reported using cocaine
intravenously and 64.4% had been arrested or had trouble with the police because of cocaine use, both significantly higher than in the other subgroups). Subtype 5 also reported the earliest age of onset of both cocaine use (mean ± standard deviation [SD] 17.9 ± 4.3 yr) and the heaviest period of cocaine use (mean ±
SD 25.8 ± 8.4 yr). The mean and SD of the membership likelihood for subtypes 4
and 5 among all participants are shown in Table 2. Subtype 4 had more AAs than
EAs in both the discovery and replication samples (Appendix 1, Table S4). Consequently, more AAs had a high membership likelihood for this subtype than
EAs. Subtype 5 was the opposite, including significantly more EAs than AAs.
The GWAS identified a total of 24 GWS (p < 5 × E−8) loci in 13 distinct gen
omic regions for which the effect on CUD was moderated by environmental
factors (see Fig. 1 and Appendix 1, Table S5, and Figures S3, S5, S7, S9, S11, S13
and S15), with little evidence of genomic inflation (λ = 1.002–1.076, Fig. 2; Appendix 1, Figures S4, S6, S8, S10, S12, S14 and S16). Table 3 shows the association results for the loci that were most representative of each region, evidenced
by the highest imputation quality, lowest p-value or both. Of the 13 GWS loci,
11 were identified with the 2 subtypes of CUD, especially subtype 5 (the
heaviest, earliest-onset subtype). In contrast, for the trait based on the DSM-5
diagnostic criterion count, only 2 variants (rs10188036 and del-13:61274071)
were GWS. From these results, the most homogeneous CUD traits, subtypes 4
and 5, yielded the most novel genetic loci in association tests. Table 4 provides
additional association results for the 13 GWS loci from tests that were performed separately among participants with and without exposure to the cor
responding childhood environmental factors in the discovery sample.
All loci except del-1:15511771 showed associations only when the moderating
effect of environmental factors was considered. For instance, the LPHN2 SNP
rs149843442 was GWS for subtype 5 in AAs (p = 3.92 × E−8) only when the effect
of household tobacco use was considered in the association test. For the same
subtype, rs114492924 in LINC0141 was GWS in AAs only when the change in
residence variable was considered. For del-1:15511771, the association test result
was 2 orders of magnitude more significant (i.e., the p-value went from 2.16 ×
E−8 to 3.61 × E−10 when the interaction effect involving nontraditional parental
care was included in the equation). Of the 13 GWS results, 11 were observed in
AAs, the 2 exceptions being rs71428385 in the fibronectin 1 gene (FN1) and
rs56337958 in TENM3. Both SNPs were associated with subtype 4 in EAs
(Table 3) only when the interactive effect of an environmental factor was included
in the model (e.g., household tobacco use for rs71428385 and traumatic experience
for rs56337958). In AAs, 2 SNPs—rs10188036 in TRAK2 and del-13:61274071 in
LINC00378—were also GWS for the DSM-5 criterion count under the interactive
effect of change in residence and household drinking and illicit drug use, respectively. All of these results demonstrate that these loci were detectable only when
considering environmental interactions in the statistical models.
Of the 13 representative loci, 7 were present in the replication data set with
good imputation quality (Appendix 1, Table S5). The interaction effect of
rs114492924 in LINC01411 (which encodes a non-protein-coding RNA) with
change in residence was successfully replicated (p = 3.63 × E−3). Three other loci
remained GWS after the results from the discovery and replication phases were
combined via meta-analysis: rs10188036 in TRAK2 (meta p = 2.95 × E−8) with the
presence of change in residence, rs149843442 near LPHN2 (approximately
77 000 bp from the 3' end of the gene; meta p = 3.50 × E−8) with the presence of
household tobacco use, and del-1:15511771 in TMEM51 (meta p = 9.11 × E−10)
with the presence of nontraditional parental care.
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Discussion

tests, but could be detected only when environmental interplay was included in the statistical association models.
Our strongest finding, the one that was GWS in the
discovery phase (p = 1.23 × E−8) and subsequently replicated in the independent sample (p = 3.63 × E−3), was for
rs114492924 in LINC01411, which encodes a long intergenic
non-protein-coding RNA. The association was evident only
in the AA population when the moderating effect of a
change in residence was considered. Participants with the
rs114492924*T allele had higher membership likelihood for
subtype 5 if they experienced a change in residence by age
13 (β = 0.27; p = 2.32 × E−8; Table 4). This association was not
evident in participants who had no such childhood experience (β = 0.02; p = 0.72; Table 4). Although the biological
function of LINC01411 is unknown, according to GTEx51 it is
predominantly expressed in brain (Appendix 1, Figure S17),
supporting its potential role in CUD risk.
Three additional variants that were GWS in the discovery
phase but not in the replication phase were GWS after

To the best of our knowledge, this is the first GWAS for CUD
that considered both the phenotypic heterogeneity of the disorder and gene–environment interplay, which examined 5 informative childhood environmental factors: change in residence, nontraditional parental care, traumatic experience,
household drinking and drug use, and household tobacco
use. The GWAS was conducted separately for AAs (n = 2070)
and EAs (n = 1570). An independent sample of AAs (n = 918)
and EAs (n = 1382) was subsequently used to replicate and
extend the findings through meta-analysis. Our results show
that it is necessary to account for both of these issues when
searching for the genetic causes of CUD. Our finding that
more loci were identified for specific CUD subtypes than for
the nondifferentiated general CUD trait based on diagnostic
criterion count illustrates the importance of identifying clin
ically homogeneous CUD subtypes. In addition, 12 of the
13 representative findings were not identified in main effect
Table 2: Sample characteristics

Characteristic
Total
Male, %
Age, mean ± SD

GWAS sample

Replication sample

Subtyping
sample

AA

EA

AA

EA

9965

2070

1570

918

1382

53.81

59.42

60.76

66.78

67.58

40.14 ± 11.12

43.14 ± 7.76

37.69 ± 10.25

44.43 ± 9.14

38.07 ± 11.47

Environmental factors, %
Nontraditional parental care

—

69.52

62.55

71.24

66.21

Change in residence

—

76.96

73.38

82.35

75.25

Traumatic experience

—

36.67

33.82

40.74

27.79

Household drinking and illicit drug use

—

61.88

58.54

62.85

56.51

Household tobacco use

—

74.59

81.40

75.71

75.33

Cocaine use disorder traits, mean ± SD
DSM-5 diagnostic criterion count

—

8.10 ± 3.06

7.56 ± 3.79

7.46 ± 3.76

6.41 ± 4.37

Membership likelihood for subtype 4

—

0.58 ± 0.40

0.32 ± 0.39

0.54 ± 0.42

0.28 ± 0.38

Membership likelihood for subtype 5

—

0.18 ± 0.31

0.35 ± 0.42

0.16 ± 0.31

0.29 ± 0.40

AA = African American; EA = European American; GWAS = genome-wide association study; SD = standard deviation.
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Fig. 1: Manhattan plot showing results from a genome-wide association study of the membership score of subtype 5 in
African Americans, moderated by household tobacco use (a childhood environmental factor).
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enced change in residence by age 13 (β = −1.91, p = 1.20 × E−8,
Table 4, versus β = 0.96, p = 0.16, for those who had not
moved). This SNP is in the trafficking kinesin-binding protein
2 gene (TRAK2) on chromosome 2. The TRAK2 protein appears to regulate endosome-to-lysosome trafficking of membrane cargo and has been linked to cholesterol efflux and
HDL biogenesis,62 as well as late-onset Alzheimer disease.63
More relevant to the current study, TRAK2 interacts with the
γ-aminobutyric acid A (GABAA) receptor. Cocaine potentiates
GABA release and leads to the inhibition of dopamine neur
ons, thus driving drug-adaptive behaviour.64 Therefore,
TRAK2 could affect the susceptibility of CUD through its protein product’s effect on the GABAA receptor.
We also identified 7 loci that had a GWS association with
CUD (5 in AAs and 2 in EAs in the discovery phase) but that
could not be tested for replication due to the lack of available
data (Table 3). The most notable of these SNPs was
rs148009780 in the synaptogyrin (SYNGR1) gene on chromosome 22. The rs148009780*T allele was associated with higher
membership likelihood for subtype 5 in AAs who experienced a change in residence (β = 0.24, p = 9.14 × E−8, Table 4,
versus β = −0.04, p = 0.56, for those who did not). SYNGR1
encodes an integral membrane protein associated with presynaptic vesicles in neuronal cells and is most highly expressed in brain (Appendix 1, Figure S19). Thus, it is a biological candidate for disorders related to the central nervous
system and variation in the gene has been associated with
schizophrenia and bipolar disorder in a southern Indian
population65 and schizophrenia in an Italian sample.66 Moreover, a recent study identified a genomic region near
SYNGR1 that is in close linkage to alcohol dependence

8

6

Observed –log10(p)

a ssociation results from the 2 phases were combined via metaanalysis. We found that del-1:15511771 was associated with
subtype 5 when the moderating effect of nontraditional
parental care was taken into account (meta p = 9.11 × E−10).
The “TG” deletion was associated with a higher membership
likelihood for subtype 5 only in AAs who had nontraditional
parental care by age 13 (β = 0.23; p = 4.99 × E−10; Table 4). The
association was not evident in those who were not exposed
to this environmental factor (β = −0.05; p = 0.34; Table 4). This
deletion variant is in TMEM5, which encodes a multi-pass
transmembrane protein. GTEx data51 show that the gene is
expressed in a wide range of human tissues, including brain
(Appendix 1, Figure S18). The mechanism of this gene’s
effects on CUD risk is unclear. However, previous data show
that the transmembrane protein coded by this gene interacts
with many chemicals, such as phenobarbital and benzopyrene.52 Thus, it would be of interest to investigate how this
protein interacts with cocaine.
Another variant that, on meta-analysis, was GWS for subtype 5 was rs149843442 (meta p = 3.50 × E−8), but was GWS
only when the moderating effect of household tobacco use
was considered. The A allele of this SNP was associated with
a higher membership likelihood for subtype 5 in AAs who
experienced household tobacco use by age 13 (β = 0.23; p =
1.04 × E−7; Table 4), an effect that was not evident in participants who were not exposed to this environmental factor (β =
−0.05; p = 0.50; Table 4). HaploReg53 shows that rs149843442
alters 5 regulatory motifs (Appendix 1, Table S7) and is in a
genomic region that overlaps with 2 potential regulatory elements indicated by chromatin modification H3K4me1 (Appendix 1, Table S6). Thus, this SNP could be functional. On
the other hand, rs149843442 is in perfect linkage disequilibrium with rs6685582 (r2 = 1, estimated using the African
population in the 1000 Genomes Project54), which was also
GWS for subtype 5 in the discovery phase (p = 4.62 × E−8),
which was also moderated by household tobacco use. However, no data were available in the replication sample to replicate this finding. We know that rs6685582 is in a very active
genomic region that overlaps with dozens of regulatory elements identified in various human tissues, including brain
(Appendix 1, Table S8), and it alters 2 regulatory motifs (Appendix 1, Table S9). Therefore, the association involving
rs149843442 could also be positional, tagging rs6685582 or
other variants that are in close linkage disequilibrium. The
regulatory elements overlapping both variants are likely involved in the regulation of LPHN2, which is their closest
gene. The 2 variants are ~77 000 to 96 000 bp from the 3' end
of the gene. LPHN2 encodes a member of the latrophilin subfamily of G-protein-coupled receptors and participates in the
regulation of exocytosis. This gene has been linked to several
human disease phenotypes,55–59 including 2 related to brain
function: electroencephalogram60 and target recognition in
entorhinal–hippocampal synapse assembly.61
The third GWS finding emerging from meta-analysis was
for rs10188036, associated with the DSM-5 diagnostic criterion
count in interaction with the environmental variable change in
residence. The rs10188036*C allele was associated with a lower
DSM-5 diagnostic criterion count only in AAs who experi-

4

2

0
0

2

4

6

Expected –log10(p)
Fig. 2: Quantile–quantile plot showing the observed distribution of
p values compared with the expected distribution for the genomewide association study of the membership score of subtype 5 in
African Americans, moderated by household tobacco use (a childhood environmental factor).
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C
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A
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G
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T
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A
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G

T

A

C

4

rs56337958*

183160533

216288777
A

G
G

A
TENM3

FN1

SYNGR1

RN7SL609P

SOGA2

TRDN

SLC7A13

RP13–20L14.1

LINC01411

LPHN2

TMEM51

LINC00378

TRAK2

Gene

Traumatic
experience

Household
tobacco use

Change in
residence

Household
tobacco use

Change in
residence

Household
tobacco use

Change in
residence

Household
drinking and
illicit drug use

Household
tobacco use

Change in
residence

Household
tobacco use

Nontraditional
parental care

Household
drinking and
illicit drug use

Change in
residence

0.09

0.08

0.10

0.07

0.14

–0.04

0.09

0.10

0.13

0.14

0.15

–1.55

–1.05

β
p

9.98 ×
E–4

4.71 ×
E–3

2.05 ×
E–4

4.92 ×
E–5

2.41 ×
E–4

6.47 ×
E–5

5.63 ×
E–3

1.36 ×
E–3

1.71 ×
E–4

7.45 ×
E–6

2.16 ×
E–8

2.75 ×
E–6

4.05 ×
E–5

Disc

—

–0.01

—

—

—

0.01

—

0.02

0.13

0.14

0.06

—

–0.86

β

0.18

—

0.09

p

—

0.84

—

—

—

0.41

—

0.73

5.71 ×
E–3

8.25 ×
E–3

Rep

Main genetic effect

Alt = alternative allele; Chr = chromosome; Disc = discovery phase; Pos = base pair position; Ref = reference allele; Rep = replication phase.
*Polymorphism not included in the replication data set.
†Replicated genome-wide significant results.
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Table 3: Results of association tests for genome-wide significant variants in the discovery sample

—

1.59 ×
E–5

—

—

—

2.45 ×
E–3

—

3.35 ×
E–3

3.47 ×
E–6

1.98 ×
E–7

3.77 ×
E–8

—

1.13 ×
E–5

Meta p

0.31

0.23

0.19

0.14

0.27

0.25

–0.07

0.26

0.23

0.27

0.23

0.23

–2.71

–1.89

β
p

3.07 ×
E–8

3.99 ×
E–8

4.74 ×
E–8

9.73 ×
E–9

4.34 ×
E–8

3.91 ×
E–8

1.54 ×
E–8

4.71 ×
E–8

3.51 ×
E–8

1.23 ×
E–8†

3.92 ×
E–8

3.61 ×
E–10

4.94 ×
E–8

1.77 ×
E–8

Disc

—

0.01

—

—

—

—

0.01

—

0.02

0.16

0.11

0.10

—

–0.97

β

0.09

0.10

—

0.12

p

—

0.89

—

—

—

—

0.73

—

0.78

3.63 ×
E–3†
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—

4.21 ×
E–5

—

—

—

—

6.36 ×
E–6

—

2.11 ×
E–6

2.11 ×
E–10†

3.50 ×
E–8†

9.11 ×
E–10†

—

2.95 ×
E–8†

Meta p

Environment-moderated genetic effect
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(LOD = 3.2) in an AA sample.67 Our findings suggest that
SYNGR1 may also regulate susceptibility to CUD. Another
variant that may be worth further investigation is rs56337958,
an intronic SNP in TENM3 on chromosome 4. The
rs56337958*G allele was associated with higher membership
likelihood for subtype 4 in EAs who had a traumatic experience by age 13 (β = 0.31, p = 4.29 × E−8, Table 4, versus β = 0.02,
p = 0.64, for those who did not). According to GTEx data,51
TENM3 encodes a large transmembrane protein that may be
involved in the regulation of neuronal development and is
expressed in many brain tissues (Appendix 1, Figure S20).
Our previous study showed the FAM53B SNP rs2629540 to
be associated to CUD criterion count in AAs.9 However, we
did not identify any variants in or near FAM53B that were
GWS in the current study, possibly because the phenotypic
definitions and covariates in this study differed from those in
the previous study. Here, the strongest signal for an association of rs2629540 with CUD was found with subtype 4 among
AAs when taking into account the moderating effect of a
change in residence (p = 1.01 × E−4). There are 2 possible ex
planations for the weaker support for the association of
FAM53B with CUD. First, the GWAS sample was smaller in
present study (3640 total) than in the previous study (5697 total),9 because we excluded people with no previous cocaine
exposure or no information on environmental factors. Second,
as noted above, the CUD-related traits tested differed in the
2 studies. In the previous study, we used 2 binary traits, cocaine dependence and cocaine-induced paranoia, and 1 quantitative trait, the DSM-IV criterion count, which contrasted
with the subtypes and DSM-5 criterion count used here.
Although childhood traumatic experience has been shown
to have a profound impact on adulthood substance use,38,39

fewer genetic variants were associated with CUD when accounting for its effect compared with the effects of other en
vironmental factors. A possible explanation for this finding is
that, compared with other factors, fewer participants in our
study had had a traumatic experience by age 13, substantially
limiting the power to detect associated variants.

Limitations
The findings in this paper should be viewed in the context
of a number of limitations. The main limitation is the lack of
availability of clinical data and high-quality genotypes to
replicate 6 of the 13 loci that were GWS in the discovery
phase. Despite the fact that databases such as dbGap (www.
ncbi.nlm.nih.gov/gap) include genotyped participants with
CUD, the phenotypic variables used in our cluster analysis
and the environmental variables used in the association
study were specific to the SSADDA diagnostic interview
and were not available in dbGap data sets. Variation in
measurements among studies is a well-recognized problem
in data aggregation.17 The 3 non-replicated loci and the
6 loci without data for replication could represent false-
positive findings from GWAS, especially those for which
there was no previous evidence supporting their potential
involvement in the biological processes contributing to
CUD. Nonetheless, among the 7 loci for which replication
data were available, 4 were GWS either in replication or
after combining results from the 2 analytic phases through
meta-analysis, so they are worthy of further investigation.
Another limitation was that the method used to derive the
5 binary environmental factors may not have been optimal.
We assigned a value of 0 or 1 to participants using a threshold

Table 4: Association between imputed alternative allele dosage of variants and phenotypes (Table 3), with and without exposure to the
corresponding childhood environmental factors in the discovery sample*
Exposed
Variant

Ref

Alt

Childhood environmental factors

β

p value

Unexposed
β

p value

DSM-5 diagnostic criterion count, African Americans
rs10188036
del-13:61274071

T

C

Change in residence

–1.91

1.20 × E–8

0.96

0.16

AT

A

Household drinking and illicit drug use

–2.75

2.17 × E–8

–0.41

0.50

Membership likelihood for subtype 5, African Americans
del-1:15511771

CTG

C

Nontraditional parental care

0.23

4.99 × E–10

–0.05

0.34

rs149843442

G

A

Household tobacco use

0.23

1.04 × E–7

–0.05

0.50

rs114492924

C

T

Change in residence

0.27

2.32 × E–8

0.02

0.72

rs139389287

T

G

Household tobacco use

0.23

7.68 × E–8

–0.05

0.41

rs148834561

A

G

Household drinking and illicit drug use

0.26

1.07 × E–7

–0.03

0.57

AG

A

Change in residence

–0.07

3.55 × E–8

–0.01

0.53

G

A

Household tobacco use

0.25

1.22 × E–7

–0.06

0.52

Change in residence

0.27

1.15 × E–7

0.04

0.59

del-17:80342628
rs75591854
rs75414569

T

C

Household tobacco use

0.14

2.61 × E–8

0.02

0.69

rs148009780

C

T

Change in residence

0.24

9.14 × E–8

–0.04

0.56

Membership likelihood for subtype 4, European Americans
rs71428385

G

A

Household tobacco use

0.14

8.38 × E–5

0.09

0.27

rs56337958

A

G

Traumatic experience

0.31

4.29 × E–8

0.02

0.64

Alt = alternative allele; Ref = reference allele.
*Results were obtained via 2 separate sets of main effect tests for the variants, using exposed and unexposed subsamples, respectively.
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based on the distribution of responses to ensure an adequate number of participants who were exposed to the environmental effects. In addition, correction may have been
needed for multiple statistical testing. Because the subtype
quantitative traits were defined by classifying participants
in one cluster from those outside the cluster, these traits
were expected to be correlated. Because there was correlation among the traits (Appendix 1, Figure S21) and among
the environmental factors (Appendix 1, Figure S22), and the
hypotheses for EAs and AAs were distinct, Bonferroni correction was too restrictive. Adjustment methods may need
to be developed to appropriately correct for testing multiple
correlated traits and environmental factors in 2 populations.
Moreover, the overlap in genotyped markers between the
discovery and replication samples was relatively small due
to the different genotyping microarrays. However, an advantage of using the samples was that the participants in
the discovery and replication samples were identically assessed by a well-validated procedure, resulting in high confidence and consistency in the phenotypes and environmental factors. Lastly, most of the variants that were identified
with association were imputed, but all had excellent INFO
scores for the imputation (Appendix 1, Table S1).

Conclusion
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